Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients

被引:50
作者
Stefani, Alessandro [1 ]
Alifano, Marco [1 ]
Bobbio, Antonio [1 ]
Grigoroiu, Madalina [1 ]
Jouni, Rami [1 ]
Magdeleinat, Pierre [1 ]
Regnard, Jean-Francois [1 ]
机构
[1] Univ Paris 05, Dept Thorac Surg, Hop Hotel Dieu, F-75004 Paris, France
关键词
STAGE-IIIA N2; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM SURVIVAL; PREOPERATIVE CHEMOTHERAPY; ENDOBRONCHIAL ULTRASOUND; SURGICAL RESECTION; NEEDLE ASPIRATION; SURGERY; THERAPY; RADIOTHERAPY;
D O I
10.1016/j.jtcvs.2010.02.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The role of surgery in patients with N2 non-small cell lung cancer is debated. The aim of this study was to evaluate the results of surgical resection after induction chemotherapy. Methods: We retrospectively reviewed the cases of patients with N2 non-small cell lung cancer who underwent neoadjuvant chemotherapy followed by resection between 2001 and 2007. They all had tumors deemed resectable. Results: One hundred seventy-five patients entered the study. Most of them received 2 or 3 cycles of chemotherapy (81%), in all cases platinum-based regimens. Chemotherapy response rate was 62%. Operations included 96 lobectomies/bilobectomies and 79 pneumonectomies. Complete resection rate was 94%, and perioperative mortality was 4.5%. A pathologic mediastinal downstaging was found in 39% of patients. Overall median survival time and 5-year survival were 34.7 months and 30%, respectively. Survival was affected by clinical response (median survival time 51 months and 5-year survival 42% for responders versus 19 months and 10% for nonresponders) and by nodal downstaging (51 months and 45% versus 25% and 22%). In the group of responders, nondownstaged patients showed satisfying survival (median survival time 30 months, 5-year survival 30%). In the group of nonresponders, survival was unsatisfactory when a lobectomy was performed (median survival time 20 months, 5-year survival 13%) and poor in case of pneumonectomy (15 months and 6%). Multivariate analysis found 4 factors significantly affecting survival: clinical response, nodal downstaging, number of chemotherapy cycles, and histopathologic response. Conclusions: Surgery after chemotherapy could be effective for selected patients with N2 non-small cell lung cancer. Survival for responders is satisfactory, even in case of persistent N2 disease. Prognosis for nonresponders is disappointing. (J Thorac Cardiovasc Surg 2010;140:356-63)
引用
收藏
页码:356 / 363
页数:8
相关论文
共 26 条
[1]   Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis [J].
Adams, K. ;
Shah, P. L. ;
Edmonds, L. ;
Lim, E. .
THORAX, 2009, 64 (09) :757-762
[2]   Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].
Albain, Kathy S. ;
Swann, R. Suzanne ;
Rusch, Valerie W. ;
Turrisi, Andrew T., III ;
Shepherd, Frances A. ;
Smith, Colum ;
Chen, Yuhchyau ;
Livingston, Robert B. ;
Feins, Richard H. ;
Gandara, David R. ;
Fry, Willard A. ;
Darling, Gail ;
Johnson, David H. ;
Green, Mark R. ;
Miller, Robert C. ;
Ley, Joanne ;
Sause, Willliam T. ;
Cox, James D. .
LANCET, 2009, 374 (9687) :379-386
[3]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[4]   Pneumonectomy after chemotherapy:: Morbidity, mortality, and long-term outcome [J].
Alifano, Marco ;
Boudaya, Mohamed S. ;
Salvi, Maurizio ;
Collet, Jean-Yves ;
Dinu, Carmen ;
Camilleri-Broet, Sophie ;
Regnard, Jean-Francois .
ANNALS OF THORACIC SURGERY, 2008, 85 (06) :1866-1873
[5]   Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].
Andre, F ;
Grunenwald, D ;
Pignon, JP ;
Dujon, A ;
Pujol, JL ;
Brichon, PY ;
Brouchet, L ;
Quoix, E ;
Westeel, V ;
Le Chevalier, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989
[6]   Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].
Betticher, DC ;
Schmitz, SFH ;
Tötsch, M ;
Hansen, E ;
Joss, C ;
von Briel, C ;
Schmid, RA ;
Pless, M ;
Habicht, J ;
Roth, AD ;
Spiliopoulos, A ;
Stahel, R ;
Weder, W ;
Stupp, R ;
Egli, F ;
Furrer, M ;
Honegger, H ;
Wernli, M ;
Cerny, T ;
Ris, HB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759
[7]   Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival [J].
Bueno, R ;
Richards, WG ;
Swanson, SJ ;
Jaklitsch, MT ;
Lukanich, JM ;
Mentzer, SJ ;
Sugarbaker, DJ .
ANNALS OF THORACIC SURGERY, 2000, 70 (06) :1826-1831
[8]   Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients [J].
De Waele, Michele ;
Serra-Mitjans, Mireia ;
Hendriks, Jeroen ;
Lauwers, Patrick ;
Belda-Sanchis, Jose ;
Van Schil, Paul ;
Rami-Porta, Ramon .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2008, 33 (05) :824-828
[9]   Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer [J].
Depierre, A ;
Milleron, B ;
Moro-Sibilot, D ;
Chevret, S ;
Quoix, E ;
Lebeau, B ;
Braun, D ;
Breton, JL ;
Lemarié, E ;
Gouva, S ;
Paillot, N ;
Bréchot, JM ;
Janicot, H ;
Lebas, FX ;
Terrioux, P ;
Clavier, J ;
Foucher, P ;
Monchâtre, M ;
Coëtmeur, D ;
Level, MC ;
Leclerc, P ;
Blanchon, F ;
Rodier, JM ;
Thiberville, L ;
Villeneuve, A ;
Westeel, V ;
Chastang, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :247-253
[10]   One hundred consecutive pneumonectornies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits [J].
Doddoli, C ;
Barlesi, F ;
Trousse, D ;
Robitail, S ;
Yena, S ;
Astoul, P ;
Giudicelli, R ;
Fuentes, P ;
Thomas, P .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (02) :416-425